An Open-Label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function.
Latest Information Update: 28 Dec 2011
At a glance
- Drugs Patupilone (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 27 Aug 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 27 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2007 New trial record.